Clinical Trial Update: A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating patritumab deruxtecan in pediatric participants with relapsed or refractory solid tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Malignant Neoplasm | Phase 1, Phase 2 | Status: RECRUITING